Camlipixant (BLU-5937) 是一种有效的、选择性的、非竞争性和具有口服活性的 P2X3 同型三聚体受体拮抗剂,对 hP2X3 同型三聚体的 IC50 为 25 nM。Camlipixant 表现出较强的止咳效果,且无味觉改变。Camlipixant 可用于不明原因、难治性慢性咳嗽的研究。 Camlipixant (BLU-5937) a potent, selective,...
在全球针对P2X3受体阻断剂的开发领域,进展较快的还有Bellus Health正在开发的Camlipixant (BLU-5937),目前已经进入临床3期研究。公开资料显示,Camlipixant的前期研究显示其在治疗慢性难治性咳嗽方面表现优异,尤其是对P2X3受体和P2X2/3受体的...
Camlipixant (BLU-5937) is a non-competitive P2X3 homotrimeric receptor antagonist and evidence from early clinical trials suggests antitussive activity in patients with refractory and unexplained chronic cough. The objective of this study was to better characterize the mechanism of action of camli...